NCT00996749

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Pilot Study to Determine the Optimal Dosage of Omega-3 Polyunsaturated Fatty Acid (PUFA) in Men With Advanced Prostate Cancer

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I trial is studying the best way to give omega-3 fatty acids in treating patients with advanced prostate cancer. Omega-3 fatty acids may slow disease progression and may be an effective treatment for patients with advanced prostate cancer

Detailed description

OBJECTIVES: I. To conduct a pilot study of omega-3 polyunsaturated fatty acid (PUFA) (omega-3 fatty acid) supplementation in a group of patients with advanced prostate cancer to assess the dose of omega-3 PUFA necessary to achieve an omega-6 to -3 ratio of 1:1 on an individual basis and to assess the clinical impact of omega-3 supplementation on disease progression OUTLINE: Patients receive long-term omega-3 polyunsaturated fatty acid (PUFA) supplementation orally (PO). After completion of study treatment, patients are followed up at 1, 6, and 12 months.

Conditions

• Stage III Prostate Cancer

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	omega-3 fatty acid	Given PO
OTHER	bone scan	Correlative studies
OTHER	dual x-ray absorptometry	Correlative studies
OTHER	laboratory biomarker analysis	Correlative studies
PROCEDURE	biopsy	Correlative studies

Timeline

• Start date: 2011-05-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2009-10-16
• Last updated: 2018-07-03